Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $13.74, for a total transaction of $109,920.00. Following the completion of the sale, the insider now owns 8,000 shares of the company’s stock, valued at approximately $109,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of CORT traded down $0.37 during trading hours on Friday, hitting $13.01. The company had a trading volume of 1,231,630 shares, compared to its average volume of 1,269,341. The firm has a market capitalization of $1.60 billion, a PE ratio of 29.57 and a beta of 1.80. Corcept Therapeutics Incorporated has a 12 month low of $11.21 and a 12 month high of $25.96.
Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.14 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.02). The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $67.42 million. Corcept Therapeutics had a net margin of 63.79% and a return on equity of 32.96%. Corcept Therapeutics’s revenue for the quarter was up 50.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 0.6 EPS for the current year.
A number of brokerages have commented on CORT. ValuEngine cut shares of Corcept Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, August 13th. B. Riley cut their price target on shares of Corcept Therapeutics from $30.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, August 13th. BidaskClub cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 14th. Cantor Fitzgerald reissued a “hold” rating and issued a $17.00 price objective on shares of Corcept Therapeutics in a research report on Friday, November 2nd. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $11.00 price objective (down from $20.00) on shares of Corcept Therapeutics in a research report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. Corcept Therapeutics presently has an average rating of “Hold” and a consensus target price of $21.83.
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.